Potassium Ion

Potassium Ion

SCHEMBL2891322

CCN(CC(=O)[O-])S(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F.[K+]

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA

The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 12/20 0.40
MMP2 P08253 12/20 0.40
MMP9 P14780 12/20 0.40
MMP8 P22894 12/20 0.40
MMP13 P45452 12/20 0.40
CA2 P00918 11/20 0.40
CA1 P00915 8/20 0.40
F2 P00734 1/20 0.33
PRSS1 P07477 1/20 0.33
PRSS2 P07478 1/20 0.33
PRSS3 P35030 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Potassium Ion SCHEMBL7972093 1.00 MMP1 (0.40) MMP1MMP2MMP9MMP8MMP13
Potassium Ion SCHEMBL7968724 1.00 MMP1 (0.40) MMP1MMP2MMP9MMP8MMP13
Potassium Ion SCHEMBL7966881 1.00 MMP1 (0.40) MMP1MMP2MMP9MMP8MMP13
Potassium Ion SCHEMBL7966004 0.98 MMP1 (0.41) MMP1MMP2MMP9MMP8MMP13
SCHEMBL25246586 0.97 MMP1 (0.40) MMP1MMP2MMP9MMP8MMP13
SCHEMBL6880862 0.97 MMP1 (0.40) MMP1MMP2MMP9MMP8MMP13
Potassium Ion SCHEMBL4154859 0.88 MMP1 (0.39) MMP1MMP2MMP9MMP8MMP13
SCHEMBL8773070 0.85 MMP1 (0.39) MMP1MMP2MMP9MMP8MMP13
SCHEMBL7971831 0.84 MMP1 (0.45) MMP1MMP2MMP9MMP8MMP13
SCHEMBL6340658 0.84 MMP1 (0.45) MMP1MMP2MMP9MMP8MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 326 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119445434-A Frame supervision video instance segmentation system with timing sequence characteristics fused 重庆位图信息技术有限公司 2025-02-14 CN claimed
CN-119028595-A Method for building open domain adaptive Alzheimer disease diagnosis model 重庆理工大学 2024-11-26 CN claimed
EP-4413969-A1 DISPERSION AND PREPARATION WITH CINEOL FOR TOPICAL USE Cineolux GmbH (DE) 2024-08-14 EP claimed
US-12630729-B2 Ink, printing apparatus, printing method, and printed matter RICOH COMPANY, LTD. (JP) 2026-05-19 US disclosed
CN-117203062-B Contact member, drying apparatus and printing apparatus 株式会社理光 2026-05-12 CN disclosed
US-20260088352-A1 Heterocyclic Electrolyte Additives for Rechargeable Metal Batteries U S ARMY DEVCOM ARMY RES LABORATORY (US) 2026-03-26 US disclosed
EP-4328248-B1 ULTRAVIOLET-CURABLE WATER-BASED INK, DISPERSION, ULTRAVIOLET-CURABLE WATER-BASED COMPOSITION AND PRINTED MATTER MITSUBISHI CHEM CORP (JP) 2026-03-18 EP disclosed
US-12578665-B2 Toner producing method RICOH COMPANY, LTD. (JP) 2026-03-17 US disclosed
EP-4703438-A1 ULTRAVIOLET-CURABLE COMPOSITION, METHOD FOR PRODUCING CURED PRODUCT, CURED PRODUCT, ULTRAVIOLET-CURABLE INK, METHOD FOR PRODUCING PRINTED MATTER, AND PRINTED MATTER Mitsubishi Chemical Corporation (JP) 2026-03-04 EP disclosed
EP-4703437-A1 ULTRAVIOLET-CURABLE COMPOSITION, METHOD FOR PRODUCING CURED PRODUCT, CURED PRODUCT, ULTRAVIOLET-CURABLE INK, METHOD FOR PRODUCING PRINTED MATTER, AND PRINTED MATTER Mitsubishi Chemical Corporation (JP) 2026-03-04 EP disclosed
CN-121582626-A Unmanned aerial vehicle target recognition method and device based on track anomaly detection 中国人民解放军军事科学院军事医学研究院 2026-02-27 CN disclosed
US-4859570-A Photosensitive element having improved antistatic layer E. I. DU PONT DE NEMOURS AND COMPANY (US) 1989-08-22 US disclosed
US-4837135-A SPUTTERED LAYER OF INDIUM-TIN OXIDE AND CHROMIUM CROSSLINKED SILVER HALIDE GELATIN EMULSION E. I. DU PONT DE NEMOURS AND COMPANY (US) 1989-06-06 US disclosed
EP-0303503-A2 Electron beam recording film E.I. DU PONT DE NEMOURS AND COMPANY (US) 1989-02-15 EP disclosed
EP-0300376-A1 Element having improved antistatic layer E.I. DU PONT DE NEMOURS AND COMPANY (US) 1989-01-25 EP disclosed
US-4778915-A WATER REPELLANT, OIL REPELLANT PROTECTIVE COATINGS FOR LEATHER ATOCHEM (FR) 1988-10-18 US disclosed
US-4472286-A FOAMING AGENTS FOR FIRE-FIGHTING CIBA-GEIGY CORPORATION (US) 1984-09-18 US disclosed
US-4420434-A WETTING AGENTS; FIRE EXTINGUISHERS; NONHYDROLYZING AMINE SALT OF CATIONIC AND ANIONIC SURFACTANT CIBA-GEIGY CORPORATION (US) 1983-12-13 US disclosed
US-4299749-A STABLE, AQUEOUS, SELF-STRIPPING FLOOR CLEANER STERLING DRUG INC. (US) 1981-11-10 US disclosed
US-4032495-A WATER-REPELLENT AND OIL-REPELLENT COMPOSITIONS BASED ON FLUORINE COMPOUND PRODUITS CHIMIQUES UGINE KUHLMANN (FR) 1977-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260088352-A1 Heterocyclic Electrolyte Additives for Rechargeable Metal Batteries CA3, CA1, HCN1 MMP1 2058/4885MMP2 1865/4885MMP9 2029/4885
US-12578665-B2 Toner producing method HEATR1, KDELR1, H1-0 MMP1 3000/4885MMP2 4158/4885MMP9 4701/4885
US-12630729-B2 Ink, printing apparatus, printing method, and printed matter RHOC, TMCO1, MAP1LC3C MMP1 279/4885MMP2 1073/4885MMP9 341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.